FAST FACTS: STATINS AND SLCO1B1/ABCG2 GENOTYPING
Pre-emptive pharmacogenomic testing has been proven to reduce adverse drug reactions.
Common Statins
- Atorvastatin and Rosuvastatin are first-line agents for preventing and managing atherosclerotic cardiovascular disease.
Adverse Effects
- Myalgia and Myopathy (Statin-Associated Musculoskeletal Symptoms or SAMS) affect up to 30% of first-time users.
- SAMS can lead to:
- Reduced adherence
- Discontinuation
- Poor therapeutic outcomes
Genetic Risk Factors
- Variants in SLCO1B1 and ABCG2 genes are linked to increased SAMS risk.
- Pre-emptive genotyping helps:
- Identify at-risk patients
- Guide alternative drug selection
- Support conservative dosing strategies
Testing Information
- SLCO1B1 and ABCG2 genotyping is included in the PHARMA pharmacogenomics panel.
- Results available within 10 working days
- Contact: pgx@ampath.co.za